Genoskin
PrivateLast Round
Series A
Sep 16, 2025
Total Funding Raised
$10.34M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Genoskin is a biotechnology company that provides ready-to-use, live human skin models for pharmaceutical, cosmetic, and chemical product testing.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Genoskin Comparables
Compare Genoskin with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ten Bio Ltd | 85% | |
| Outer Biosciences | 82% | |
| REVIVO BioSystems | 80% |
Genoskin Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 16, 2025 | ||||
| Debt | Sep 16, 2025 | ||||
| Grant | Oct 28, 2020 | ||||
| Grant | Aug 29, 2019 | ||||
| Grant | Mar 7, 2018 | ||||
Early Funding | Aug 29, 2017 |
Key People
Founding team and executive leadership
Genoskin Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GSO Innovation | Series A |
| European Regional Development Fund | Grant |
| Finorpa | Series A |
| Région Occitanie | Grant |
| CA Toulouse 31 Initiatives | Series A |
| Caisse d'Epargne Midi-Pyrénées | Debt, Series A |
| OCCTE | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 27, 2026
Fabrice Bouteille appointed to strengthen governance.
- Sep 16, 2025
New production sites opened in France and the United States.
Recent news
Latest coverage and updates
- expands_offices_inJul 16, 2026
Genoskin, Inc. expands offices in United States, Northern America, Americas.
- expands_facilitiesJun 29, 2026
Genoskin Inc. expands facilities to United States, Northern America, Americas.
- launchesJun 29, 2026
Genoskin Inc. launches primary human mast cells.
Genoskin Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Genoskin's valuation, stock price, and market status.
Is Genoskin a public or private company?
Genoskin is a private company.
What is the current stock price of Genoskin?
Genoskin is a private company with no public stock price. No recent secondary market data is available.
How much is Genoskin worth (valuation)?
Valuation information for Genoskin is not publicly available.
Can I buy Genoskin stock?
Genoskin shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Genoskin's last funding round?
Genoskin's most recent funding round was Debt on September 16, 2025.
Who are the main investors in Genoskin?
Key investors in Genoskin include OCCTE.
Will Genoskin IPO soon?
No public IPO plans have been announced for Genoskin.
How can I track Genoskin secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Genoskin's secondary market activity and sign up for updates.